Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
New MS blood test to launch in Europe
Siemens Healthineers has received CE Mark approval for its test for the management of relapsing multiple sclerosis, allowing it to be launched in Europe.
Read more
RSV drug nirsevimab chases FDA approval
A drug to treat infants with RSV is on its pathway to approval in the US following a successful Biologics License Application to the FDA.
Pharma's sustainability agenda centre stage in new ABPI report
Global action is required to ensure pharma’s commitments to reach Net Zero are realised, according to a new ABPI report.
Pfizer joins GSK in RSV success
Pfizer plans to file for approval for its RSV vaccine for infants by the end of 2022 after achieving positive Phase 3 results.
First RSV vaccine for older adults earns pivotal Phase 3 results
A first-in-class vaccine for respiratory syncytial virus has shown to be highly efficacious in a Phase III trial, GSK has announced.
Promising outlook for integrating young talent in pharma
Collaboration between the pharmaceutical industry and academia is on the rise, according to a recent survey from the ABPI.
Pfizer-BioNTech assemble with the Avengers in COVID booster drive
Pfizer and BioNTech collaborate with Marvel on a comic encouraging COVID-19 booster vaccinations in the US.
Moderna joins BIA as 500th member
Moderna has joined the UK’s BioIndustry Association (BIA), taking the trade association’s membership to over 500 companies.
GSK and Microsoft tackle Nepal disease transmission
A new disease surveillance project to curb the spread of known and unknown pathogens, especially mosquito-borne illnesses, has been launched by GSK and Microsoft in Nepal.
Loading posts...
« Previous
1
…
3
4
5
6
7
…
9
Next »